KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $4.2 billion.

  • Alnylam Pharmaceuticals' Total Liabilities rose 10.21% to $4.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.2 billion, marking a year-over-year increase of 10.21%. This contributed to the annual value of $4.2 billion for FY2025, which is 10.21% up from last year.
  • Alnylam Pharmaceuticals' Total Liabilities amounted to $4.2 billion in Q4 2025, which was up 10.21% from $4.6 billion recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Total Liabilities ranged from a high of $4.6 billion in Q3 2025 and a low of $2.3 billion during Q1 2021
  • For the 5-year period, Alnylam Pharmaceuticals' Total Liabilities averaged around $3.7 billion, with its median value being $3.9 billion (2023).
  • Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 15046.69% in 2021, then grew by 10.21% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Total Liabilities (Quarter) stood at $3.1 billion in 2021, then increased by 21.26% to $3.7 billion in 2022, then grew by 9.34% to $4.1 billion in 2023, then rose by 3.02% to $4.2 billion in 2024, then rose by 0.1% to $4.2 billion in 2025.
  • Its Total Liabilities stands at $4.2 billion for Q4 2025, versus $4.6 billion for Q3 2025 and $4.3 billion for Q2 2025.